UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO) exercised 9,500 options and sold 9,350 United Therapeutics Corp common shares held via trusts on July 16, 2026 under a 10b5‑1 plan.

On July 16, 2026, United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring 9,500 shares of United Therapeutics common stock, and on the same day sold a total of 9,350 shares in a series of open‑market transactions at weighted average prices ranging from approximately $527.31 to $537.11 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. The sales yielded aggregate proceeds of roughly $4.99 million, while the option exercise cost about $1.29 million, implying a substantial spread monetization. After these transactions, Rothblatt’s indirect holdings via trusts remain significant at approximately 331,910 shares, plus additional directly and indirectly held common stock and options listed in the filing, with the bulk of the activity reflecting planned option-exercise-and-sell transactions rather than discretionary buying or selling.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000100

Alert Tier

7